IP Library Granted Patent US 11,465,976
Granted Patent B2
US 11,465,976 · App. 16/945,854 · Granted Oct 11, 2022

1,2,4-oxadiazole and thiadiazole compounds as immunomodulators

Inventors: Pottayil Govindan N. Sasikumar (Bangalore, IN); Muralidhara Ramachandra (Bangalore, IN); Seetharamaiah Setty Sudarshan Naremaddepalli (Bangalore, IN)
Assignee: Aurigene Discovery Technologies Limited
C07D271/06A61K31/4245A61K38/05A61K45/06A61P35/00C07D271/10C07D413/04C07D413/06C07D413/12C07K5/06078C07K5/0812
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,465,976
App. No.
16/945,854
Granted
Oct 11, 2022
Kind
B2
Abstract

The present invention relates to 1,2,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

Claims (45)

1. A method of treating cancer in a subject in need thereof, comprising administering to the subject a compound selected from:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

9. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

10. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

11. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

12. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

13. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

14. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

15. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

16. The method of claim 1 , wherein the compound is

17. The method of claim 1 , wherein the compound is

18. The method of claim 1 , wherein the compound is

19. The method of claim 1 , wherein the compound is

20. The method of claim 1 , wherein the compound is

21. The method of claim 1 , wherein the compound is

22. The method of claim 1 , wherein the compound is

23. The method of claim 1 , wherein the compound is

24. The method of claim 1 , wherein the compound is

25. The method of claim 1 , wherein the compound is

26. The method of claim 1 , wherein the compound is

27. The method of claim 1 , wherein the compound is

28. The method of claim 1 , wherein the compound is

29. The method of claim 1 , wherein the compound is

30. The method of claim 1 , wherein the cancer is selected from lung cancer, breast cancer, colon cancer, renal cancer, bladder cancer, thyroid cancer, prostate cancer, osteosarcoma, or Hodgkin's lymphoma.

Assignments (1)
CHANGE OF NAME Recorded May 16, 2023
From: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
To: AURIGENE ONCOLOGY LIMITED
Reel/Frame 063654/0411 →
Priority Claims (2)
IN 1178/CHE/2015 · Mar 10, 2015 · national
IN 1180/CHE/2015 · Mar 10, 2015 · national
Continuity (2)
Continuation 15556800
Related Publication 20200361880A1 · Nov 19, 2020
Cited By (4)
US 12,187,689 US 12,226,402 US 12,252,475 US 12,643,870